Introduction
============

Estrogen receptors (ERs) are members of the nuclear receptor (NR) superfamily that mediate the pleiotropic effects of the steroid hormone estrogen in a diverse range of developmental and physiological processes \[[@B1]\]. Although estrogens are important physiological regulators in the reproductive system, in bone metabolism, and in the maintenance of the cardiovascular and central nervous systems, they have also been associated pathologically with an increased risk for breast and endometrial cancer \[[@B2]-[@B5]\]. Consequently, ERs have been found to be essential in the initiation and development of most of these cancers. Current endocrine therapies for ER-positive breast cancers are primarily designed to target either estrogen or ER levels and/or activity. Use of a partial antiestrogen, tamoxifen, in the management of early-stage breast cancer has clearly demonstrated an increase in both disease-free and overall survival. In addition, recent studies demonstrate that tamoxifen can be used as a chemopreventive agent for hormone-dependent breast cancer. The major concerns of long-term therapy with tamoxifen are its uterotropic effects, which result in an increased risk for endometrial cancer, and the acquired clinical resistance to tamoxifen. This has led to the active pursuit of better selective ER modulators (SERMs) that display the optimal agonistic or antagonistic activities in various estrogen target tissues.

In this article we review the emerging studies of ER action that reveal the roles of a wide spectrum of receptor coregulators and their interaction with other cellular signaling pathways. An understanding of the molecular factors that modulate the activity of the estrogen-signaling network provides insight into the mechanism by which SERMs exert their tissue-specific effects. The identification of factors that are responsible for such effects is enabling the development of new ways to overcome resistance to endocrine therapy.

ERα and ERβ: structure
======================

Two mammalian ERs have been identified, ERα and ERβ, encoded by independent genes \[[@B6]-[@B8]\]. ERα was cloned nearly two decades ago and was believed for many years to be the only ER. The subsequent cloning of ERβ increased the complexity of estrogen signaling. Both ER isoforms share modular structures characteristic of the NR superfamily, which include six functional domains (Fig. [1](#F1){ref-type="fig"}) \[[@B9]\]. The most conserved domain is the central DNA-binding domain (DBD, region C), followed by the ligand-binding domain (LBD, region E). The LBD also contains a dimerization surface and a ligand-dependent activation function 2 (AF-2). AF-2 undergoes a marked conformational change in the presence of different ligands, and determines the subsequent binding of coactivators or corepressors. Activation function 1 (AF-1), located in the N-terminal A/B domain, is regulated by growth factors and its activity depends on the cellular and promoter context. AF-1 and AF-2 act synergistically to attain maximal receptor transcriptional activity. Although both ERα and ERβ display similar binding affinities for 17β-estradiol (E2), they have different roles in the regulation of gene expression. The low level of conservation within the A/B domains of ERα and ERβ might be responsible for these functional differences between the two receptors by interacting with unique sets of transcription factors.

ER exerts its transcriptional effects through both direct and indirect binding to specific DNA sites, termed estrogen response elements (EREs), located in the promoter and/or enhancer regions of target genes \[[@B10]\]. The consensus EREs consist of two inverted, palindromic half-sites of PuGGTCA motifs. ER can bind EREs as ERα or ERβ homodimers or as ERαβ heterodimers. The affinity and the specificity of ER binding are determined by both the sequence and spatial organization of the motifs \[[@B11],[@B12]\]. In addition to signaling directly through EREs, ER can act more as a coactivator to modulate transcriptional responses via interactions with other classes of DNA-bound transcription factors, such as AP-1 or SP-1 \[[@B13],[@B14]\]. These different modes of ER action have been suggested to have an important role in determining differential responses to various ER ligands.

Ligand-dependent ER-mediated transcription: coregulators
========================================================

It is now recognized that ER-mediated transcription is a highly complex process involving a multitude of coregulatory factors and \'cross-talk\' between distinct signaling pathways (Fig. [2](#F2){ref-type="fig"}) (reviewed in \[[@B15]\]). The existence of intermediary factors in the ER action was suggested by several observations, including the tissue-specific activities of tamoxifen and the cross-squelching observed between cotransfected receptors in transcription assays. By following this lead and using biochemical approaches as well as yeast two-hybrid screens, over 30 coregulatory molecules have been identified. For simplicity they can be broadly divided into coactivators, which augment the activity of receptors, and corepressors, which mediate the repressive effects of receptors (reviewed in \[[@B16]\]).

Transcriptional activation involves alterations in chromatin structure mediated by ATP-dependent chromatin-remodeling enzymes in conjunction with factors that contain histone acetyltransferase (HAT) activity \[[@B17]\]. Consistent with this concept is the observation that ER recruits BRG1, a mammalian homologue of a component of the SWI/SNF chromatin remodeling complex, to EREs in a cooperative manner with HATs \[[@B18]\]. Further, many ER coactivators possess intrinsic HAT activities, including CBP/p300, p/CAF, and TAF~II~250 \[[@B19]-[@B21]\]. Other coactivators such as the p160 coactivators facilitate ER transcription by serving as platforms to recruit HATs and protein methyltransferases.

There are three members of the p160 family of coactivators, NCoA-1 (SRC-1) \[[@B22]\], NCoA-2 (TIF2, GRIP1) \[[@B23],[@B24]\], and NCoA-3 (AIB1, ACTR, RAC3, p/CIP, TRAM-1) \[[@B25]-[@B30]\], which share extensive structural homology. They all contain a bHLH--PAS (basic helix--loop--helix--Per/ARNT/Sim) domain in the amino-terminus. Although this domain mediates DNA binding in other factors that contain it, no evidence of direct contact of the p160 coactivators with DNA has been demonstrated. In the central region of the p160 proteins there is a domain that mediates the interaction of p160 coactivators to the LBD of agonist-bound ER through several short helical motifs with the sequence LXXLL \[[@B31]\]. The C-terminal region of the p160 proteins mediates interaction with other factors with a role in ER signaling including CBP (CREB-binding protein), p300 and arginine methyltransferase 1 (CARM-1) \[[@B32]\].

In spite of significant sequence homology between p160 members, several lines of evidence suggest that in addition to some degree of functional redundancy they have unique functions as well. Although all three p160 coactivators are widely expressed at low levels in a number of tissues, they exhibit high levels of expression in selective tissues. NCoA-1 has relatively high levels of expression in the brain and pituitary \[[@B33]\], whereas NCoA-2 has the highest levels in the testis \[[@B23]\], and NCoA-3 in the thyroid gland, thymus, kidney, lung, and skin \[[@B34]\]. Further, the levels of expression of these coactivators are hormonally regulated. For example, thyroid hormone upregulates NCoA-1 mRNA levels in the anterior pituitary, whereas E2 downregulates its expression \[[@B33]\]. Both the mRNA and protein levels of NCoA-3 can be suppressed by E2, and this repression is reversed by antiestrogens or all-*trans*retinoic acid \[[@B35]\].

More evidence of their distinct physiological functions comes from knockout mouse models. Deletion of the gene encoding NCoA-1 in mice resulted in only mild defects in hormone target tissues such as uterus, mammary gland, testis, and prostate. These tissues exhibit decreased growth and development in response to steroid hormones in the absence of NCoA-1 \[[@B36]\]. In addition, disruption of NCoA-1 causes a delay in Purkinje cell development and the maturation of the cerebellum leading to moderate motor dysfunction in adulthood \[[@B37]\]. Genetic deletion of NCoA-3 leads to a different spectrum of phenotypes, including stunted somatic growth, delayed puberty, abnormal reproductive function and retarded mammary ductal growth \[[@B34],[@B38]\]. The more severe defects observed in the mammary gland in these mice suggests that NCoA-3 might have a more pronounced role in regulating mammary gland functions.

In addition to the chromatin remodeling complexes and the p160 family, a wide spectrum of coactivators has been found to interact with ER. These include DRIP205/ TRAP220/PBP, a component of the DRIP/TRAP mediator complex \[[@B39]-[@B41]\], PGC-1, a tissue- and promoter-specific PPARγ-coactivator-1 \[[@B42],[@B43]\], SNURF, a small nuclear C(3)HC(4) finger protein \[[@B44]\], PELP1, a proline-, glutamic acid-, leucine-rich protein 1 \[[@B45]\], and NCoA-7 (ERAP140), a structurally distinct coactivator \[[@B46]\]. With the exception of NCoA-7, most of these coactivators possess the canonical LXXLL motif that mediates their agonist-induced interaction with the ER LBD. The common mode of interaction of a large number of coactivators involving the LXXLL motif with most of the nuclear receptor raises the problem of a potential lack of specificity. One solution to this problem might be that sequences flanking the core motif can determine receptor selectivity, as suggested by phage display experiments \[[@B47]\].

In contrast to these factors that all bind to the ER LBD, some coactivators, such as the steroid receptor RNA activator SRA and the RNA helicases p68/p72, interact with and regulate the AF-1 domain of ER \[[@B48]-[@B50]\]. GT198, a tissue-specific and kinase-regulated coactivator, interacts with the ER DNA-binding domain. GT198 differs from other coactivators in that it regulates basal receptor activity and hormone sensitivity \[[@B51]\]. Some ER-interacting proteins have other distinct biological functions. Cyclin D1, a protein frequently overexpressed in breast cancer, has been shown to activate unliganded ER through recruiting p160 coactivators and p/CAF \[[@B52]-[@B55]\]. The calcium-binding protein calmodulin and the activating enzyme of NEDD8, Uba3, both regulate ER activity by modulating the steady-state level of the receptor \[[@B56],[@B57]\]. The Sma and MAD-related protein 3 (SMAD3) interacts with ER, allowing cross-talk between the estrogen and the transforming growth factor-β signaling pathways \[[@B58]\]. Similarly, MNAR, a modulator of nongenomic activity of ER, modulates ER interaction with members of the Src family of tyrosine kinases, leading to stimulation of their enzymatic activity, which in turn enhances ER transcriptional activity \[[@B59]\].

Opposing the mechanism by which coactivators effect transcriptional activation by modulating chromatin state, NR corepressors negatively regulate transcription via their recruitment of histone deacetylases (HDACs). The best characterized corepressors are the structurally related proteins N-CoR and SMRT, which interact with the repressive form of nuclear receptors such as the unliganded retinoic acid and thyroid hormone receptors \[[@B60],[@B61]\]. In the case of ER, both N-CoR and SMRT bind ER in the presence of antagonists such as tamoxifen and are recruited to the promoter of target genes \[[@B62]-[@B65]\]. Other proteins act to repress ER-mediated transcription by distinct mechanisms \[[@B66]-[@B69]\]. Examples include the ER-specific corepressor REA, as well as the orphan receptors SHP and DAX-1, which act by competing with the p160 coactivators for binding agonist-bound ER.

Structure of the ER LBD
=======================

Complementing the molecular studies of ER regulation, structural analyses of the ER LBD have shed further light on our understanding of ER function, in particular its interaction with coactivators and the structural basis of receptor agonism and antagonism. A wide repertoire of structurally and chemically distinct compounds bind to ER. Some of these compounds, such as the natural ligand E2 and the synthetic diethylstilbestrol (DES), act as receptor agonists, whereas others compete for E2 binding and act as antagonists. Structural studies of the ER LBD have established that ER ligands have a profound effect on the receptor structure. The structure of ER LBD exhibits a α-helical sandwich topology distinctive of NR LBDs: it consists of 12 helices (H1--H12) arranged in three anti-parallel layers separated by β-sheets \[[@B70]\]. Although the overall conformation of the ER LBD is quite similar in the presence of various compounds, the carboxy-terminal transactivation domain (AF-2, H12) is highly sensitive to the nature of the bound ligand.

Structures of ER LBD in complex with E2, DES, the SERMs raloxifene and tamoxifen, and the pure antiestrogen ICI 164,384, an analogue of fulvestrant (ICI 182,780), have been determined \[[@B71]-[@B74]\]. ER agonists induce a major conformational change in the receptor: H12 is repositioned and aligned over the ligand-binding cavity, resulting in a specific binding site for the consensus LXXLL motif of the coactivators \[[@B75],[@B76]\]. However, binding of raloxifene or tamoxifen sterically hinders the H12 positioning and prevents the formation of the coactivator-binding surface \[[@B71]-[@B73]\]. The pure antiestrogen ICI 164,384 elicits an unusual organization of the LBD \[[@B74]\]. ICI 164,384 is a 7α-alkylamide analog of E2 and its protruding 7α sidechain substituent sterically prevents H12 from aligning over the ligand-binding cavity; further, the positioning of the terminal amide portion of the sidechain occludes H12 from adopting its alternative position over the coactivator-binding cleft. Consequently, ICI 164,384 seems to completely abolish H12 association with the LBD, which might be crucial for generating its full antagonist effect. However, our increased understanding of the structural changes induced by various ER ligands has yet to allow the design of a SERM with an optimal balance between the agonistic and antagonistic properties in the desired target tissues.

Ligand-independent ER activation: cross-talk with other signaling pathways
==========================================================================

ER regulation is not limited to direct ligand binding, because it can also be modulated by several other pathways. These include the epidermal growth factor (EGF) and insulin-like growth factor-1 (IGF1) mitogenic pathways and the second messengers cyclic AMP (cAMP) and dopamine (reviewed in \[[@B77]-[@B79]\]) (Fig. [2](#F2){ref-type="fig"}). Activation of these pathways influences ER transcriptional activity either by targeting the receptor directly or by regulating the activities of receptor coregulators. For instance, activation of epidermal growth factor receptor (EGFR) by EGF leads to phosphorylation of the Ser118 residue in the ERα AF-1 domain by p44/42 mitogen-activated protein kinase (MAPK), which in turn recruits the coactivator p68/p72 and activates target gene transcription in a ligand-independent manner \[[@B80],[@B81]\]. In contrast, ligand-dependent S118 phosphorylation is mediated through the association of ERα with TFIIH and the cyclin-dependent kinase CDK7 \[[@B82],[@B83]\]. In addition, the activation of protein kinase A (PKA) by cAMP results in ER phosphorylation and increased transactivation of an ERE-containing reporter \[[@B84],[@B85]\]. One report suggests that Ser236 phosphorylation by PKA inhibits ER dimerization, and this inhibition can be reversed by E2 \[[@B86]\].

ER coregulators are also targets of many of the same signaling pathways that affect ER directly. MAPK can phosphorylate p160 coactivators NCoA-1 and NCoA-3, and can enhance their transcriptional activities partly by facilitating their interaction with CBP/p300 \[[@B87],[@B88]\]. CBP itself can also be phosphorylated and activated through the p42/44 MAPK cascade \[[@B89]-[@B91]\]. Phosphorylation of CBP by both MAPK \[[@B92]\] and cyclin-dependent kinases (CDKs) leads to an upregulation of its HAT activity \[[@B93]\].

Although it has been well established that growth factors can modulate ER transcriptional activity, the observation that activated ER can transmit signals that modulate these signal transduction pathways has been more difficult to dissect. Studies suggest that E2-bound ER can activate the extracellular signal-regulated kinase (ERK) or the phosphoinositide 3-kinase (PI3K), leading to the activation of downstream signaling molecules \[[@B94],[@B95]\]. The existence of transcription-independent ER functions increases the potential diversity of ER signaling. It remains to be determined which physiological and pathological activities of ER are dependent on its non-genomic activities.

ER and breast cancer
====================

An important role for ER in breast cancer has been known for almost 30 years \[[@B96]\]. Although both ERα and ERβ have been implicated, the role of ERβ in breast cancer remains elusive (reviewed in \[[@B97]\]). ERα is expressed in a subset of normal breast epithelial cells, and ERα-containing epithelial cells do not normally proliferate in response to estrogen \[[@B98]\]. In this view, estrogen stimulates the normal mammary epithelium to secrete growth factors that stimulate neighboring ER-negative epithelial cells to proliferate in a paracrine fashion. In contrast to the normal breast, most pre-malignant breast lesions express high levels of ERα, and ERα-expressing breast cancer cells are hormone-dependent and undergo regression when estrogen is removed (reviewed in \[[@B99]\]). Thus, ERα is a well-established predictive marker of hormone sensitivity in breast cancer as well as a positive prognostic marker. Further, the presence of ERα in breast cancer at the time of diagnosis is an indication for endocrine therapy. In the advanced disease setting, many patients with ERα-positive breast tumors will respond favorably, at least initially, to endocrine therapies.

Because ER-positive breast cancer is estrogen-dependent, reducing estrogen levels or altering the activity of the receptor can induce these cancers to regress. Oophorectomy remains an option for premenopausal women with ER-positive tumors; however, medical rather than surgical approaches are more widely used. Current approaches designed to reduce levels of circulating estrogen include selective aromatase inhibitors and luteinizing-hormone-releasing hormone (LHRH) agonists. Drugs that target ER fall into two major classes. These include SERMs such as tamoxifen and the pure antiestrogens such as fulvestrant, which reduce ER concentrations.

Menopausal status has an important role in determining therapy (Fig. [3](#F3){ref-type="fig"}). Small, randomized trials in premenopausal women have suggested that tamoxifen brings treatment benefits similar to those with oophorectomy. Moreover, tamoxifen can be used effectively as a second-line endocrine therapy after oophorectomy, and vice versa \[[@B100],[@B101]\]. In postmenopausal women, the primary source of estrogen is not from ovarian synthesis but from the conversion of androstenedione to estrone and estradiol in the peripheral tissues including the breast. Aromatase inhibitors block the final step in the conversion of androgen to estrogen and have been widely used in the treatment of postmenopausal women with advanced breast cancer (reviewed in \[[@B102],[@B103]\]).

The current aromatase inhibitors used are the third-generation inhibitors and are much better tolerated than their nonselective predecessors. They can be divided into nonsteroidal (anastrazole and letrozole) and steroidal (exemestane) inhibitors (Fig. [4](#F4){ref-type="fig"}). Anastrazole was the first aromatase inhibitor to be approved for second-line treatment of advanced breast cancer in postmenopausal women; letrozole and exemestane were later found to have similar efficacy \[[@B104]-[@B107]\]. And recently, both anastrazole and letrozole were shown to have a higher efficacy than tamoxifen as first-line therapy for patients with advanced ER-positive tumors \[[@B108],[@B109]\]. The efficacy of aromatase inhibitors as adjuvant therapy is currently being tested in the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial \[[@B110]\].

Tamoxifen and SERMs
===================

The concept of manipulating the endocrine system in the treatment of breast cancer was developed more than 100 years ago, after the first demonstration that oophorectomy could lead to regression of the disease in premenopausal women with metastatic breast cancer \[[@B111]\]. Subsequently, this concept has led to the development of effective and relatively safe drugs, such as tamoxifen \[[@B112],[@B113]\].

Tamoxifen is a first-generation non-steroidal SERM and is currently the most frequently prescribed drug for the treatment of all stages of breast cancer. Tamoxifen was approved by the Food and Drug Administration (FDA) in 1977 for the treatment of women with advanced breast cancer, in 1986 for adjuvant treatment of primary breast cancer, and later in 1990 for adjuvant therapy in premenopausal and postmenopausal women with node-negative disease (reviewed in \[[@B113],[@B114]\]). For women with ER-positive breast tumors, tamoxifen results in a 50% annual reduction in the recurrence rate and a 28% annual reduction in the death rate \[[@B115],[@B116]\]. Women with metastatic disease who have ER-positive tumors also benefit from treatment with tamoxifen \[[@B117]\]. In addition, findings that tamoxifen could reduce the incidence of contralateral breast cancer led to breast cancer prevention trials \[[@B118]\]. The Breast Cancer Prevention Trial (BCRT) demonstrated that tamoxifen can be used as a preventive therapy because it reduced the incidence of ER-positive breast cancer by about 50% \[[@B119],[@B120]\]. The results of the International Breast Cancer Intervention Study (IBIS-1) also showed a more than 30% reduction in the risk for breast cancer in tamoxifen-treated group compared with placebo. There was, however, a significantly higher rate of venous thromboembolic events in the tamoxifen group, raising the concern of overall risk:benefit ratio for the pro-phylactic use of tamoxifen \[[@B121]\].

The success of tamoxifen is based on a balance between its agonistic and antagonistic activities. Tamoxifen is an antagonist in the breast, whereas it has agonist effects on bone, serum lipid profile, and the cardiovascular system \[[@B122]-[@B126]\]. The antiestrogenic activity of tamoxifen in the breast is mediated by its competitive inhibition of estrogen binding to ER and the recruitment of corepessors rather than coactivators to target promoters \[[@B127],[@B128]\]. Although the efficacy of tamoxifen in treating breast cancer has been attributed to both its cytostatic and cytotoxic effects \[[@B129]-[@B133]\], the critical targets remain to be defined.

A serious adverse effect of tamoxifen is an increased incidence of endometrial cancer due to its undesirable agonistic activity in the uterus \[[@B134],[@B135]\]. Compelling evidence suggests that the estrogenic effect of tamoxifen is highly dependent on the tissue, the cell, and the promoter context. Work from several groups has implicated various coregulators as the mediators of these cell-type and promoter-specific effects. In one model, tamoxifen inhibits the activation of the ER AF-2 domain but does not inhibit AF-1 activity, allowing AF-1 to recruit coactivators such as steroid hormone receptor coactivator-1 (SRC-1) and p68 \[[@B49],[@B136],[@B137]\]. In contrast, the expression level of corepressors such as SMRT and N-CoR has been suggested to have a role in the antagonist activity of tamoxifen: blocking N-CoR or SMRT expression might convert tamoxifen into an agonist \[[@B138]\]. In mouse embryonic fibroblasts (MEFs) from N-CoR^-/-^animals, tamoxifen functions as a full agonist on ER-regulated transcription, and the introduction of N-CoR expression in these MEFs reverses this effect \[[@B139]\].

In addition to the level of expression, the level of corepressor binding can influence SERM effects on ER activity \[[@B64]\]. However, when Morrison and co-workers inhibited the N-CoR activity by a dominant-negative N-CoR construct in MCF-7 cells, the transcriptional activity of ER was not altered by treatment with tamoxifen. Correspondingly, the histone acetylation levels in the promoters of the endogenous estrogen-responsive genes were unchanged in cells expressing the dominant-negative N-CoR construct, regardless of ligand. *In vitro*cell proliferation and *in vivo*tumor growth were also unaffected in these cells. These results suggest that corepressors other than N-CoR might be involved in the ability of tamoxifen to repress estrogen-responsive transcription and tumor growth \[[@B140]\]. Nevertheless, compelling evidence supports the notion that binding to selective coregulatory factors on a specific target gene promoter in a given tissue or cell type determines the agonistic/antagonistic activity of tamoxifen. In certain tissues such as the uterus, in which the AF-1 activity is more significant, the agonistic activity of tamoxifen is predominant \[[@B141]\]. Recent work has demonstrated that, in endometrial cancer cells, tamoxifen acts like estrogen by stimulating the recruitment of coactivators to the non-classical target gene promoters, and this requires a higher level of p160 coactivators \[[@B128]\].

The undesirable estrogenic activity of tamoxifen in the uterus has fueled the search for better SERMs. Two additional SERMs have been approved by the FDA for clinical use in the USA: toremifen for the treatment of advanced breast cancer and raloxifene for the prevention and treatment of postmenopausal osteoporosis (Fig. [4](#F4){ref-type="fig"}). Like tamoxifen, toremifene is a derivative of triphenylethylene and thus has very similar efficacy and side-effect profiles to those of tamoxifen, and exhibits cross-resistance with tamoxifen \[[@B142]-[@B144]\]. Raloxifene is a nonsteroidal benzothiophene and has a somewhat different profile of activities. When raloxifene was tested in the Multiple Outcomes Raloxifene Evaluation (MORE) trial for its effect on bone mineral density and vertebral fracture incidence in postmenopauseal women with osteoporosis, it was found to have clear benefits in decreasing the risk for vertebral fractures and in increasing bone density. Moreover, raloxifene was reported to reduce the risk for invasive breast cancer by 72% and the risk for ER-positive breast cancer by 84% \[[@B145]\]. This, together with the observation that raloxifene does not increase the risk for endometrial cancer, raised the question whether raloxifene would have advantages over tamoxifen as a chemopreventive agent in women at increased risk for breast cancer. The ongoing STAR (Study of Tamoxifen And Raloxifene) trial should resolve this issue \[[@B146]\].

In addition to a role for coregulators in determining the spectrum of SERM activity, other mechanisms are probably important (reviewed in \[[@B147]-[@B150]\]). For example, ERβ is expressed only in certain target tissues, and its responses to various ligands are distinct from those of ERα \[[@B151]-[@B153]\]. Thus, the biological activities of SERMs are determined by a multitude of mechanisms. It is hoped that an understanding of these mechanisms in detail will lead to the development of new SERMs with the desired clinical profile.

Tamoxifen resistance
====================

The efficacy of tamoxifen in many patients with breast cancer is limited by a couple of factors. First, only 60--70% of the breast tumors are ER-positive, and the anti-tumor activity of tamoxifen is observed exclusively in tumors that express ER. Second, almost all patients with advanced breast cancer who initially respond to tamoxifen therapy will eventually develop resistance to the therapy. Potential genetic or epigenetic changes within the tumor that might contribute to tamoxifen resistance include the following: altered ER expression; hypersensitivity of ER to low levels of circulating estrogen due to ER mutations or variants that lead to constitutively transcriptionally active ER; altered levels and/or activities of coactivators and corepressors that lead to ER activation, rather than inhibition, by tamoxifen; and ligand-independent ER activity stimulated by aberrant expression of growth factors. Although loss of ER expression has been reported in a few cases of tamoxifen resistance \[[@B154]\], most of the acquired resistance is not due to alteration in the ER status, and many of these tumors respond to second-line endocrine therapies.

Differences in mechanisms by which tamoxifen and other endocrine therapies affect ER function might define patterns of cross-resistance between tamoxifen and the second-line therapy. Cross-resistance between triphenylethylenes, for instance tamoxifen and toremifene, has been clearly demonstrated in breast cancer patients. This is also true of tamoxifen and raloxifene. In contrast, the pure antiestrogen fulvestrant can induce responses in patients who have failed to respond to tamoxifen. Aromatase inhibitors have also produced significant responses as second-line therapies after antiestrogens.

We have reviewed above that recruitment of coactivators or corepressors to ER has a role in determining the switch between receptor activation and repression, and the coordinated action of ligand, receptor, and coregulators contributes to distinct patterns of gene expression in biological settings. Cumulative evidence suggests that intricate modulation of the receptor:coregulator ratio in distinct cells and tissues determines their response or resistance to endocrine therapy. The p160 coactivator, AIB1 (for \'amplified in breast cancer\'), was identified on the basis of its frequent amplification in breast cancer \[[@B25]\]. Overexpression of AIB1 mRNA and protein has been revealed in more than 60% and roughly 10% of the breast tumors, respectively \[[@B155],[@B156]\]. High levels of both AIB1 and HER-2 protein in breast tumors have been recently associated with tamoxifen resistance. A potential mechanism of this resistance involves activation of the MAPK cascade resulting from increased signaling from HER-2, which in turn activates AIB1, and the high level of AIB1-mediated ER activity increases the agonistic activity of tamoxifen \[[@B157]\]. Conversely, low mRNA levels of the corepressor N-CoR have been associated with resistance to tamoxifen \[[@B158]\]. Identifying aberrant coregulators will assist in designing future therapeutic applications to improve the efficacy of the current endocrine therapy. It remains a challenge to dissect the regulation of a specific coregulator in a given cell or tissue type in response to SERMs and to target the factors without having detrimental effects because these factors are also involved in mediating responses from a variety of signaling pathways.

Apart from hormonal therapies that directly target estrogen--ER signaling, inhibitors of growth factor activity have attracted increasing interest in the treatment of breast cancer. EGFR and ErbB-2/HER-2/neu are examples of growth factor signaling molecules that are being targeted for breast cancer. Overexpression of EGFR or expression of a truncated and constitutively active form of EGFR is found in some breast cancers \[[@B159]-[@B161]\]. More importantly, HER-2 amplification is found in about 25% of breast cancers and is correlated with poor disease-free survival and resistance to chemotherapy and endocrine therapy (reviewed in \[[@B162]\]).

Strategies to target EGFR and ErbB-2/HER-2/neu include antireceptor antibodies, tyrosine kinase inhibitors, ligand--toxin conjugates, and receptor antisense molecules (reviewed in \[[@B163]\]). The tyrosine kinase inhibitor Iressa (ZD 1839, gefitinib) was developed mainly for the treatment of advanced lung cancers but has been shown in phase I/II trials to have potential benefits in other solid tumors, including breast cancer. Treatment with Iressa can inhibit growth of breast cancer cell lines *in vitro*that are resistant to tamoxifen and fulvestrant. Moreover, when used concurrently with either of the antiestrogens, Iressa prevented the development of resistance \[[@B164]\]. Trastuzumab (Herceptin), a humanized monoclonal antibody directed against the extracellular domain of the HER-2 protein, is the first HER-2-directed therapy that has gained approval from the US FDA for the treatment of patients with metastatic breast cancer \[[@B165]\]. Several phase II trials have indicated that trastuzumab has synergistic or additive effects in combination with chemotherapies and hormonal agents. *In vitro*studies have shown that treatment with trastuzumab in HER-2-overexpressing breast cancer cells can restore cell sensitivity to both estrogen and tamoxifen \[[@B163]\].

Other nuclear receptor-targeted therapies
=========================================

In addition to ER, progesterone receptor is targeted in the treatment of advanced receptor-positive breast cancer. However, because of their side-effect profile, progestins are in general now used as third-line or fourth-line therapy \[[@B166]\]. Other agents currently under development for the prevention and treatment of breast cancer include the ligands of other nuclear receptors. Retinoids, ligands for the retinoic acid receptors (RARs and RXRs), have been shown to inhibit cell proliferation in breast cancer cells \[[@B167]-[@B171]\]. Other nuclear receptor ligands that have been shown to exhibit inhibitory effects on breast cancer include those for PPARγ and VDR (vitamin D receptor) (reviewed in \[[@B172]-[@B174]\]). Although this is an area of active investigation, none of these compounds has yet made it to the clinic.

Conclusions and future perspectives
===================================

The ER signaling hierarchy is far from isolated from other cellular signaling cascades. It integrates multiple signals from both hormonal ligands and other extracellular and intracellular stimuli in coordination with an array of cofactor complexes, and regulates both physiological and pathological processes. The clinical limitation of the first-generation SERM, tamoxifen, has fueled an intense search for newer and better SERMs. The ultimate goal of the SERM research is to find a molecule that has all the benefits of estrogen, none of its adverse effects, and offers protection against breast cancer. To achieve this goal, a better understanding is needed of how the orchestrated action of SERM, receptor, and coregulators contribute to distinct patterns of gene expression. Multiple studies have supported the hypothesis that intricate modulation of the receptor--coregulator interaction on a specific target gene promoter in a given tissue, cell, or tumor context can dictate the degree and direction of SERM action.

Dissecting the interrelationship between ER and its coregulators may open the door for the rational design of novel therapeutics. The cellular dynamics of these cofactor complexes are beginning to be elucidated with assays such as chromatin immunoprecipitation (ChIP) and real-time imaging techniques. An understanding of how the program of ER-regulated transcription is dysregulated in breast cancer and how it changes with the development of resistance to endocrine therapy will lead to improved strategies for the use of existing endocrine therapies and for the development of new and more effective agents for the prevention and treatment of breast cancer.
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![ER regulation by a variety of signals. Growth factors such as epidermal growth factor, insulin-like growth factor-1, insulin, and transforming growth factor-β bind to and activate their receptors, which in turn activate the RAS--RAF--ERK and the phosphoinositide 3-kinase (PI3K) pathways; the activated kinases then phosphorylate and activate ER. Other extracellular stimuli such as dopamine and cyclic AMP bind G-protein-coupled receptors and activate adenylyl cyclase (AC) and protein kinase A (PKA), which subsequently phosphorylate and activate ER. ER can also interact directly with components of the cytosolic signaling molecules, including the regulatory subunit of PI3K, leading to the activation of the serine/threonine kinase Akt. In the nucleus, hormone binding results in receptor dimerization and recruitment of coactivators or corepressors depending on the bound ligand, leading to transcriptional activation or repression. ERE, estrogen response element; MEK, MAP kinase/ERK kinase; SERM, selective estrogen receptor modulator.](bcr742-2){#F2}
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![Chemical structures of the three FDA-approved selective estrogen receptor modulators (SERMs), the pure antiestrogen Faslodex, and the aromatase inhibitors (AIs). The SERMs include the triphenylethylenes tamoxifen and toremifene, and the benzothiophene raloxifene. AIs include the nonsteroidal anastrazole and letrozole, and the steroidal exemestane.](bcr742-4){#F4}
